Journal Watch
- PDF / 198,737 Bytes
- 14 Pages / 612 x 792 pts (letter) Page_size
- 30 Downloads / 208 Views
Pharm Med 2010; 24 (2): 121-134 1178-2595/10/0002-0121/$49.95/0
ª 2010 Adis Data Information BV. All rights reserved.
Journal Watch
Contents 1. First, Catch Your Signal!. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122 2. Measuring Quality of Life for Certain Events versus Pre-Specified Points in Time. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122 3. Healthcare Rationing by Proxy: Cost-Effectiveness Analysis and the Misuse of the $50 000 Threshold in the US . . . . . . . . . . . . . . . . 122 4. Ongoing Pharmaceutical Reforms in France: Implications for Key Stakeholder Groups. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123 5. Detecting Adaptive Immunity: Applications in Transplantation Monitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123 6. Gene Therapy in Parkinson’s Disease: Rationale and Current Status . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123 7. Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease: Rationale and Current Evidence . . . . . . . . . . . . . . . . . . . . . 124 8. Is the Societal Approach Wide Enough to Include Relatives?: Incorporating Relatives’ Costs and Effects in a Cost-Effectiveness Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124 9. Analytical Strategies for Characterizing Chemotherapy Diffusion with Patient-Level Population-Based Data . . . . . . . . . . . . . . . . . 125 10. Minimizing Repolarization-Related Proarrhythmic Risk in Drug Development and Clinical Practice . . . . . . . . . . . . . . . . . . . . . . . . . . 125 11. Evaluation of In Vivo P-Glycoprotein Phenotyping Probes: A Need for Validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126 12. Molecular Signatures of Ovarian Cancer: From Detection to Prognosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126 13. A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment . . . . . . . . . . . . . . . . . . . . . . . . . 126 14. Anticytokine Therapy for Osteoarthritis: Evidence to Date . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127 15. Biodegradable Intraocular Therapies for Retinal Disorders: Progress to Date . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127 16. Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy: Implications for Risk Assessment, Prevention and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Data Loading...
